Table 6.

Expression profiling of congestive heart failure (CHF).

Target tissue	Experimental design	Number of genes affected
End-stage dilated cardiomyopathy (CM) [91]	Failing versus non-failing	103
End-stage dilated CM [92]	Failing versus non-failing	100
CM [93]	Dilated versus ischaemic myocardial tissu	192
Human heart [94]	Four groups: i) left ventricle (LV); ii) LV from failing hearts affected by dilated CM); iii) LV from failing hearts affected by ischaemic CM; iv) right ventricl	1,306
Human heart [98]	End-stage ischaemic and dilated CM	12 (in CHF) 5 (exclusive to CHF) 2 (exclusive to non-CHF)
Idiopathic dilated CM [101]	Pro-apoptotic genes	T umour necrosis factor- a signalling pathway
Idiopathic dilated CM [102]	Left ventricular assist device (LVAD) suppor	1,374 genes were reported as 'increased' and 1,629 as 'decreased'
End-stage CHF [103]	LVAD support	47 (pre- versus post-LVA D)
End-stage CHF [104]	LVAD support	T wo distinct groups identifiable with present or absent LVAD
End-stage CHF [105]	LVAD support	Focus on apelin